Hypothesis

Microbiome‑derived indole‑3‑propionic acid (IPA) activates the pregnane X receptor (PXR) in intestinal epithelial cells (IECs) to redirect the unfolding protein response (UPR) from chaperone‑mediated refolding toward a controlled aggregation pathway that yields autophagy‑compatible, protease‑resistant inclusions. This IPA‑PXR‑driven aggregation serves as a protective sequestration strategy that limits toxic oligomer accumulation, preserves barrier function, and mitigates age‑related proteostatic collapse.

Mechanistic Rationale

1. PXR as a transcriptional coordinator of proteostasis – Beyond its xenobiotic detox role, PXR directly upregulates genes encoding ER‑associated degradation (ERAD) components (e.g., HERPUD1, SEL1L), selective autophagy receptors (e.g., SQSTM1/p62), and specific small heat‑shock proteins (HSPB1, HSPB8) that promote ordered aggregation rather than amorphous clumping [1][2].
2. Coupling to IRE1β‑dependent goblet cell programming – In IECs, IRE1β signaling drives mucin (MUC2) synthesis and granule formation. IPA‑PXR activation enhances IRE1β’s RNase activity toward XBP1s while attenuating its RIDD function, biasing the UPR toward adaptive splicing and away from mRNA decay that would exacerbate misfolded load.
3. Switch from soluble oligomers to amyloid‑like aggregates – PXR‑induced HSPB8 and BAG3 facilitate the conversion of misfolded transmembrane proteins (e.g., mutant CFTR, aberrant mucin domains) into β‑sheet‑rich, thioflavin‑S‑positive inclusions that are readily recognized by p62 and recruited into autophagosomes. This mirrors the ‘protective aggregation’ described for stress‑induced granules but is modulated by a microbial metabolite.
4. Barrier preservation via reduced proteotoxic stress – By sequestering dangerous species into inert inclusions, IPA‑PXR signaling lowers chronic PERK‑eIF2α‑ATF4 signaling, decreases CHOP‑mediated apoptosis, and maintains tight‑junction protein (occludin, claudin‑4) expression, thereby preserving mucus thickness and paracellular resistance.

Testable Predictions

• In vitro IEC models (e.g., HT29‑MTX or primary murine goblet cells) treated with 10‑µM IPA will show:
  • A decrease in soluble oligomer levels of a reporter aggregation‑prone protein (e.g., mutant MUC2‑ΔC) measured by filter‑trap assay.
  • A concurrent increase in insoluble, thioflavin‑S‑positive aggregates that colocalize with LC3 and p62, demonstrable by confocal microscopy and co‑immunoprecipitation.
  • These shifts will be abolished by PXR knockout (CRISPR) or pharmacological antagonism (GSK‑066), resulting in elevated BiP, phospho‑eIF2α, and CHOP, and increased paracellular flux of FITC‑dextran.
• In vivo, germ‑free mice receiving IPA‑supplemented water (5 mg/L) from 12 to 24 months will exhibit:
  • Reduced intestinal tissue accumulation of ubiquitin‑positive aggregates (immunohistochemistry).
  • Improved mucus layer thickness ( Alcian blue staining) and decreased serum LPS‑binding protein.
  • These benefits will be lost in IEC‑specific PXR‑null mice, confirming the epithelial‑cell‑autonomous nature of the effect.
• Mechanistic epistasis: Overexpression of HSPB8 in IECs will phenocopy IPA treatment, reducing oligomer load even in the absence of IPA, whereas HSPB8 knock‑down will block IPA’s protective aggregation despite intact PXR signaling.

Falsifiability

If IPA fails to alter the solubility or autophagic targeting of aggregation‑prone IEC proteins, or if PXR manipulation does not modify barrier outcomes independent of microbial composition, the hypothesis would be refuted. Conversely, confirmation would establish a direct microbial metabolite–nuclear receptor–proteostasis axis that converts proteostatic crisis into a structured, cytoprotective response, re‑defining therapeutic strategies for age‑related intestinal barrier decline.

References

[1] https://pmc.ncbi.nlm.nih.gov/articles/PMC11770430/ [2] https://pmc.ncbi.nlm.nih.gov/articles/PMC12375546/